Clinical Trial Search

Primary: Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 — 14.8; 67.9; 57.5 percentage of participants — p=<0.0001

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 14; 13; 25; 28 participants

Primary: Change in Social Isolation Measured by Friendship Scale — 18.75; 19.72; 18.94; 20.27 units on a scale

Primary: Western Ontario Rotator Cuff Index (WORC) — 84.4; 81.7 units on a scale — p=0.60

Primary: Number of Participants With Serious Adverse Drug Reactions (ADRs) — 2 Participants

Primary: Mean Total Symptom Score (TSS) Elicited by a 1 Hour (h) Cold Dry Air (CDA) Challenge, 1 h and 24 h on Day 14 to Compare the Effect of 14 Day Repeat Dosing of Intranasal…

Primary: Identify and Utilization of Primary Care Provider (PCP) — 426; 114; 771 Participants — p=0.624

Primary: Percentage of Participants Adherent to Treatment at Month 6 — 43.3 percentage of participants

Primary: Overall Participants Preference for Nasal Spray Based on Selected Product Attributes at the End of Crossover Dosing — 72; 39; 9; 77 Participants — p=0.003

Primary: Psoriasis Area Severity Index (PASI)75 Success at Visit 6 — 4; 7; 4; 5 Participants — p=0.884

Primary: Participants With Urine Cultures With Bacteriuria (>100,000 Cfu/ml or >=100,000 Cfu/ml) Plus Pyuria (Any WBC) — 26; 32; 21; 27 participants

Primary: Change in Total Nasal Symptom Score (TNSS) From Baseline to Post-treatment. — 2.3; 2.2 Scores on a scale

Primary: Quantitative Assessment of Air Embolism to the Brain After Completion of Open Left Heart Surgery — 46; 32 gaseous cerebral microemboli — p=1.00

Primary: Time to Biochemical Failure Cumulative Incidence Percentile — 7.6; 6.8; 14.9; 12.4 Months — p=0.65

Primary: Change in Lean Mass Measured by DXA — -2.9; -2.3 Kg